ArticleJournal of orthopaedic surgery and research2025
miR-29c-3p downregulation accelerates spinal cord injury progression by targeting BRD4.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSpinal cord injury (SCI) can cause severe motor and sensory deficits below the injury site. Studies have highlighted the multifaceted regulatory roles of miR-29c-3p in neuronal development and function; however, its role in SCI remains unclear.
methodsIn this research 105 healthy controls and 159 patients with SCI were recruited. The miR-29c-3p and BRD4 levels in serum or cells were estimated by RT-qPCR. The diagnostic performance of miR-29c-3p was assessed by ROC curve. Moreover, cell viability and apoptosis were measured via CCK8 and flow cytometry. The pro-inflammatory cytokines were examined by ELISA assay. The pathological condition of SCI was modeled with LPS-induced PC12 cells. The target relationship between miR-29c-3p and BRD4 was verified by the dual-luciferase reporter assay.
resultsSerum miR-29c-3p was remarkedly decreased in the SCI population and showed high clinical diagnostic performance. Under pathological conditions, the upregulation of miR-29c-3p effectively reversed the significant reduction in cell viability and the increase in apoptosis rate. Moreover, enhanced pro-inflammatory cytokines including TNF-α, IL-6 and IL-1β were also attenuated by the upregulation of miR-29c-3p. BRD4 was identified as a target of miR-29c-3p and negatively regulated by miR-29c-3p.
conclusionsA decrease in miR-29c-3p is a promising diagnostic indicator for SCI, and downregulation of miR-29c-3p accelerates the progression of SCI by targeting BRD4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.